Physician profile
Vasvi Singh
NPI 1659652816
$405,274.68
in general payments reported to CMS, 2019-2025
26 companies · $240K in 2025
The $240K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19K · 2021: $365 · 2022: $14K · 2023: $17K · 2024: $115K · 2025: $240K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $271K · Travel and Lodging: $51K · Consulting Fee: $37K · Food and Beverage: $8,057 · Honoraria: $6,000 · Education: $9.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $271,143.08 |
| Travel and Lodging | $50,899.40 |
| Consulting Fee | $36,677.50 |
| Food and Beverage | $8,057.08 |
| Honoraria | $6,000.00 |
| Education | $9.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $162,632.29 | 2022-2025 | Wainua, Brilinta |
| Pfizer INC. | $139,125.39 | 2020-2025 | |
| Bridgebio Pharma, INC. | $72,672.20 | 2025 | Attruby |
| Alnylam Pharmaceuticals INC. | $22,230.33 | 2021-2025 | Amvuttra, Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $6,551.47 | 2021-2025 | Lifevest |
| Amgen INC. | $302.42 | 2021-2025 | Repatha |
| Ge Healthcare | $250.62 | 2021-2025 | |
| Irhythm Technologies, INC. | $246.36 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Boston Scientific Corporation | $192.16 | 2022-2024 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $143.65 | 2021-2025 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.75 | 2022-2024 | Jardiance |
| Heartflow, INC. | $110.53 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $98.41 | 2024 | Evkeeza |
| Novo Nordisk INC | $83.83 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $79.99 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $63.84 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $62.61 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $59.49 | 2024 | Xarelto |
| Amarin Pharma, INC. | $54.82 | 2021 | |
| Sanofi-Aventis U.S. LLC | $53.72 | 2021 | |
| Lemaitre Vascular, INC. | $42.83 | 2022 | |
| Tactile Systems Technology INC | $24.38 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.03 | 2021 | |
| Abbott Laboratories | $16.61 | 2023 | Mitraclip |
| Kiniksa Pharmaceuticals International, Plc | $13.94 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $13.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vasvi Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.